Biocon Limited (BOM:532523)
India · Delayed Price · Currency is INR 425.65
+0.10 (0.02%)
At close: Jul 31, 2026
Biocon Revenue
In the fiscal year ending March 31, 2026, Biocon had annual revenue of 169.27B INR with 10.91% growth. Biocon had revenue of 45.17B in the quarter ending March 31, 2026, with 2.25% growth.
Revenue
169.27B
Revenue Growth
+10.91%
P/S Ratio
4.07
Revenue / Employee
10.29M
Employees
16,447
Market Cap
689.42B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 169.27B | 16.65B | 10.91% |
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aarti Drugs | 26.78B |
| Hester Biosciences | 3.27B |
| Titan Biotech | 2.06B |
| Zenotech Laboratories | 405.19M |
| Bharat Immunologicals & Biologicals Corporation | 76.50M |
| Hindustan Bio Sciences | 4.02M |
| Transgene Biotek | 2.11M |
| CCME Global | 350.00K |
Biocon News
- 3 days ago - Roche sues Biocon over proposed breast-cancer drug copy - Reuters
- 20 days ago - Mylan to sell up to $363 million stake in India's Biocon, term sheet shows - Reuters
- 4 weeks ago - Pharma sector stocks today, July 1: Panacea Biotec surges 4.30%, Biocon jumps 1.78%, Wockhardt up 1.66% - Business Upturn
- 4 weeks ago - Top stocks to buy: Stock market recommendations for today - check list - The Times of India
- 5 weeks ago - Kiran Mazumdar-Shaw calls Bengaluru 'garbage city', sparks debate - The Times of India
- 5 weeks ago - Biocon's partner Duopharma Biotech secures over MYR 225 million in insulin tenders in Malaysia - Business Upturn
- 5 weeks ago - Biocon announces 10% final dividend for FY 2025-26 with TDS details - Business Upturn
- 7 weeks ago - Accessing capital still difficult for women entrepreneurs today: Biocon founder Kiran Mazumdar-Shaw - The Times of India